CN103347528A - 富含多酚的鳄梨果肉和/或果皮提取物及含有它的美容用、皮肤病用和营养品用组合物 - Google Patents
富含多酚的鳄梨果肉和/或果皮提取物及含有它的美容用、皮肤病用和营养品用组合物 Download PDFInfo
- Publication number
- CN103347528A CN103347528A CN2011800622964A CN201180062296A CN103347528A CN 103347528 A CN103347528 A CN 103347528A CN 2011800622964 A CN2011800622964 A CN 2011800622964A CN 201180062296 A CN201180062296 A CN 201180062296A CN 103347528 A CN103347528 A CN 103347528A
- Authority
- CN
- China
- Prior art keywords
- extract
- polyphenol
- preferred
- avocado tree
- american avocado
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 146
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 87
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 239000002537 cosmetic Substances 0.000 title claims abstract description 6
- 235000008673 Persea americana Nutrition 0.000 title claims description 87
- 240000002426 Persea americana var. drymifolia Species 0.000 title description 2
- 239000002417 nutraceutical Substances 0.000 title 1
- 235000021436 nutraceutical agent Nutrition 0.000 title 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 31
- 229940074391 gallic acid Drugs 0.000 claims abstract description 24
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 24
- 239000002253 acid Substances 0.000 claims abstract description 6
- 244000025272 Persea americana Species 0.000 claims description 88
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- 229920002770 condensed tannin Polymers 0.000 claims description 29
- OXQKEKGBFMQTML-UHFFFAOYSA-N alpha-Glucoheptitol Chemical compound OCC(O)C(O)C(O)C(O)C(O)CO OXQKEKGBFMQTML-UHFFFAOYSA-N 0.000 claims description 26
- 239000003921 oil Substances 0.000 claims description 21
- 235000019198 oils Nutrition 0.000 claims description 21
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 17
- 230000003796 beauty Effects 0.000 claims description 17
- 235000004883 caffeic acid Nutrition 0.000 claims description 17
- 229940074360 caffeic acid Drugs 0.000 claims description 17
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 17
- 235000013399 edible fruits Nutrition 0.000 claims description 17
- 208000017520 skin disease Diseases 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 16
- HSNZZMHEPUFJNZ-QMTIVRBISA-N D-keto-manno-heptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-QMTIVRBISA-N 0.000 claims description 15
- 230000003213 activating effect Effects 0.000 claims description 15
- 210000004877 mucosa Anatomy 0.000 claims description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 108090000765 processed proteins & peptides Chemical class 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 13
- 241001597008 Nomeidae Species 0.000 claims description 12
- 230000002421 anti-septic effect Effects 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 11
- 230000008591 skin barrier function Effects 0.000 claims description 11
- NHZLLKNRTDIFAD-UHFFFAOYSA-N 2,5-dihydro-1,3-oxazole Chemical compound C1OCN=C1 NHZLLKNRTDIFAD-UHFFFAOYSA-N 0.000 claims description 10
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 claims description 10
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 claims description 10
- 150000001298 alcohols Chemical class 0.000 claims description 10
- 230000007794 irritation Effects 0.000 claims description 10
- 206010048768 Dermatosis Diseases 0.000 claims description 9
- 240000000759 Lepidium meyenii Species 0.000 claims description 9
- 235000000421 Lepidium meyenii Nutrition 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 235000012902 lepidium meyenii Nutrition 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000003974 emollient agent Substances 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 230000036285 pathological change Effects 0.000 claims description 8
- 231100000915 pathological change Toxicity 0.000 claims description 8
- 230000008521 reorganization Effects 0.000 claims description 8
- 229940107161 cholesterol Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000000475 sunscreen effect Effects 0.000 claims description 7
- 239000000516 sunscreening agent Substances 0.000 claims description 7
- 230000002087 whitening effect Effects 0.000 claims description 7
- 208000035484 Cellulite Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 210000003746 feather Anatomy 0.000 claims description 6
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims description 5
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 5
- 240000006162 Chenopodium quinoa Species 0.000 claims description 5
- 208000003351 Melanosis Diseases 0.000 claims description 5
- 229930182558 Sterol Natural products 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 230000003780 keratinization Effects 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- 210000002374 sebum Anatomy 0.000 claims description 5
- 235000003702 sterols Nutrition 0.000 claims description 5
- 206010059245 Angiopathy Diseases 0.000 claims description 4
- 229920000189 Arabinogalactan Polymers 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 206010007882 Cellulitis Diseases 0.000 claims description 4
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 241000219745 Lupinus Species 0.000 claims description 4
- 240000007594 Oryza sativa Species 0.000 claims description 4
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000019312 arabinogalactan Nutrition 0.000 claims description 4
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 150000002333 glycines Chemical class 0.000 claims description 4
- 230000000474 nursing effect Effects 0.000 claims description 4
- 239000010773 plant oil Substances 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 230000037307 sensitive skin Effects 0.000 claims description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical class C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 claims description 3
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 3
- 239000001904 Arabinogalactan Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 229940124091 Keratolytic Drugs 0.000 claims description 3
- 206010049752 Peau d'orange Diseases 0.000 claims description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000000578 anorexic effect Effects 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 230000036232 cellulite Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 230000002584 immunomodulator Effects 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000001530 keratinolytic effect Effects 0.000 claims description 3
- 230000004132 lipogenesis Effects 0.000 claims description 3
- 239000004531 microgranule Substances 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims description 3
- 238000000956 solid--liquid extraction Methods 0.000 claims description 3
- 239000013638 trimer Substances 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 229960001296 zinc oxide Drugs 0.000 claims description 3
- 244000020998 Acacia farnesiana Species 0.000 claims description 2
- 235000003074 Acacia farnesiana Nutrition 0.000 claims description 2
- CTMGYVXDOVJJQM-UHFFFAOYSA-N C(CCCCCCCCCC)C1=C(C(=O)O)C=CC(C1C(=O)O)(C)CO Chemical compound C(CCCCCCCCCC)C1=C(C(=O)O)C=CC(C1C(=O)O)(C)CO CTMGYVXDOVJJQM-UHFFFAOYSA-N 0.000 claims description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 2
- SAVLIIGUQOSOEP-UHFFFAOYSA-N N-octanoylglycine Chemical compound CCCCCCCC(=O)NCC(O)=O SAVLIIGUQOSOEP-UHFFFAOYSA-N 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000010775 animal oil Substances 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000007854 depigmenting agent Substances 0.000 claims description 2
- 150000002240 furans Chemical class 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- 229940067631 phospholipid Drugs 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- FREPJBZLNPPGDM-UHFFFAOYSA-N 4,4-dimethyl-2-undecyl-5h-1,3-oxazole Chemical compound CCCCCCCCCCCC1=NC(C)(C)CO1 FREPJBZLNPPGDM-UHFFFAOYSA-N 0.000 claims 2
- RSDFPCQESXIWFY-UHFFFAOYSA-N (2-heptadecyl-4-methyl-5h-1,3-oxazol-4-yl)methanol Chemical compound CCCCCCCCCCCCCCCCCC1=NC(C)(CO)CO1 RSDFPCQESXIWFY-UHFFFAOYSA-N 0.000 claims 1
- VBFBQEURBQANIX-UHFFFAOYSA-N (4-ethyl-2-undecyl-5h-1,3-oxazol-4-yl)methanol Chemical compound CCCCCCCCCCCC1=NC(CC)(CO)CO1 VBFBQEURBQANIX-UHFFFAOYSA-N 0.000 claims 1
- 239000012754 barrier agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 claims 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 claims 1
- 150000002918 oxazolines Chemical class 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 6
- 210000004400 mucous membrane Anatomy 0.000 abstract 2
- 230000021332 multicellular organism growth Effects 0.000 abstract 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 abstract 1
- 235000020739 avocado extract Nutrition 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920002414 procyanidin Polymers 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 24
- 239000000047 product Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 235000011187 glycerol Nutrition 0.000 description 14
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000002752 melanocyte Anatomy 0.000 description 9
- 230000035876 healing Effects 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 7
- 239000007791 liquid phase Substances 0.000 description 7
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 208000001840 Dandruff Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 206010048222 Xerosis Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004493 neutrocyte Anatomy 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 235000011236 Persea americana var americana Nutrition 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000004905 finger nail Anatomy 0.000 description 3
- 210000004195 gingiva Anatomy 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- -1 phenethyl caffeic acid ester Chemical compound 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004223 radioprotective effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229930013915 (+)-catechin Natural products 0.000 description 2
- 235000007219 (+)-catechin Nutrition 0.000 description 2
- 229930013783 (-)-epicatechin Natural products 0.000 description 2
- 235000007355 (-)-epicatechin Nutrition 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical class O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 108700034262 4-Nle-7-Phe-alpha- MSH Proteins 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012444 Dermatitis diaper Diseases 0.000 description 2
- 208000003105 Diaper Rash Diseases 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- UAHFGYDRQSXQEB-LEBBXHLNSA-N afamelanotide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 UAHFGYDRQSXQEB-LEBBXHLNSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 108010028309 kalinin Proteins 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003101 melanogenic effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 229940081510 piroctone olamine Drugs 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000037309 reepithelialization Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000002966 varnish Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- KTZNZCYTXQYEHT-UHFFFAOYSA-N (2E)-N-(4-aminobutyl)-3-(3,4-dihydroxyphenyl)prop-2-enamide Natural products NCCCCNC(=O)C=CC1=CC=C(O)C(O)=C1 KTZNZCYTXQYEHT-UHFFFAOYSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- FCKUBAVAZWFDNQ-DFWYDOINSA-N (2s)-5-oxopyrrolidine-2-carboxylic acid;zinc Chemical compound [Zn].OC(=O)[C@@H]1CCC(=O)N1 FCKUBAVAZWFDNQ-DFWYDOINSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- HUXWBFFRUHXOBU-CPRQJHDUSA-N (E,5R,6S,7R,8R)-1-(3,4-dihydroxyphenyl)-5,6,7,8,9-pentahydroxynon-1-ene-3,4-dione Chemical compound C(\C=C\C1=CC(O)=C(O)C=C1)(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO HUXWBFFRUHXOBU-CPRQJHDUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- CTXGTHVAWRBISV-UHFFFAOYSA-N 2-hydroxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCO CTXGTHVAWRBISV-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MRDAXWGGWWDUKL-VKJPNVGWSA-N 3-O-Caffeoylshikimic acid Chemical compound O[C@H]1[C@H](O)CC(C(O)=O)=C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 MRDAXWGGWWDUKL-VKJPNVGWSA-N 0.000 description 1
- BLANPKHHDVIMSA-UHFFFAOYSA-N 4-(1h-indol-5-yl)oxan-4-ol Chemical compound C=1C=C2NC=CC2=CC=1C1(O)CCOCC1 BLANPKHHDVIMSA-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910018134 Al-Mg Inorganic materials 0.000 description 1
- 229910018467 Al—Mg Inorganic materials 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- XAFPURGXVZDMJH-LLVAEMQGSA-N CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO.CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO.CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO XAFPURGXVZDMJH-LLVAEMQGSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- SWGKAHCIOQPKFW-JTNORFRNSA-N Caftaric acid Chemical compound OC(=O)[C@H](O)[C@H](C(O)=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-JTNORFRNSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 244000227271 Cleome gynandra Species 0.000 description 1
- 235000012469 Cleome gynandra Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 229940119155 Histamine release inhibitor Drugs 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 241000091577 Mexicana Species 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- KTZNZCYTXQYEHT-GQCTYLIASA-N N-caffeoylputrescine Chemical compound NCCCCNC(=O)\C=C\C1=CC=C(O)C(O)=C1 KTZNZCYTXQYEHT-GQCTYLIASA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- QLDNWJOJCDIMKK-UHFFFAOYSA-N Obtusifoliol Natural products CC12CCC(O)C(C)C1CCC1=C2CCC2(C)C(C(C)CCC(=C)C(C)C)CCC21 QLDNWJOJCDIMKK-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920000124 Prodelphinidin Polymers 0.000 description 1
- 229930182448 Prodelphinidin Natural products 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 241000100615 Senegalia macrostachya Species 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 244000042314 Vigna unguiculata Species 0.000 description 1
- 235000010722 Vigna unguiculata Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Chemical class CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- WQSDYZZEIBAPIN-UHFFFAOYSA-N caffeoylglucose Natural products OC1C(O)C(O)C(CO)OC1OC(=O)C=CC1=CC=C(O)C(O)=C1 WQSDYZZEIBAPIN-UHFFFAOYSA-N 0.000 description 1
- SWGKAHCIOQPKFW-GHMZBOCLSA-N caffeoyltartaric acid Natural products OC(=O)[C@H](O)[C@H](C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-GHMZBOCLSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229940080421 coco glucoside Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000009231 family therapy Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000003301 histamine release inhibitor Substances 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 230000002065 hypopigmenting effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- PMKQSEYPLQIEAY-UHFFFAOYSA-N trans-caffeoyl-L-malic acid Natural products OC(=O)CC(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 PMKQSEYPLQIEAY-UHFFFAOYSA-N 0.000 description 1
- SWGKAHCIOQPKFW-UHFFFAOYSA-N trans-caffeoyl-tartaric acid Natural products OC(=O)C(O)C(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- PZXFWBWBWODQCS-UHFFFAOYSA-L zinc;2-carboxyphenolate Chemical compound [Zn+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O PZXFWBWBWODQCS-UHFFFAOYSA-L 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/03—Products from fruits or vegetables; Preparation or treatment thereof consisting of whole pieces or fragments without mashing the original pieces
- A23L19/07—Fruit waste products, e.g. from citrus peel or seeds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种富含多酚的鳄梨果实提取物,含有的多酚重量以没食子酸当量计,为获得的干燥提取物重量的至少10%,其中所述多酚优选含有前花青素、咖啡酸及咖啡酸衍生物,其重量以没食子酸当量计,特别为多酚总重量的至少70%。本发明还涉及一种组合物,含有作为活性剂的发明所述提取物及适宜的赋形剂。本发明还涉及一种这样的组合物或提取物用于预防或治疗皮肤、粘膜或体表生长物(superficial body growths)的紊乱或病理状况。最后,本发明涉及一种包括施予该组合物或提取物的美容护理方法,用于改善皮肤、体表生长物或粘膜的状态或外观。
Description
本发明涉及一种富含多酚的鳄梨果实,特别是鳄梨果肉和/或果皮,的提取物,以及含有该提取物和任选适宜载体的美容用、皮肤病用和营养品用组合物。
本发明的目的还在于提供一种提取富含多酚的鳄梨提取物的提取方法,以及所述方法得到的提取物。
本发明还涉及使用这种组合物或这种提取物以预防或治疗皮肤、粘膜或附属器的紊乱或病变。最后,本发明涉及一种包括施予该组合物或提取物的美容护理方法,用于改善皮肤、体表生长物或粘膜的状态或外观。
鳄梨树(Persea americana或Persea gratissim)属于樟科。
鳄梨的品种多样。在分布最广的品种中,可提及的有哈斯(Hass)、福尔特(Fuerte)、额廷格(Ettinger)培根(Bacon)、呐巴尔(Nabal)、阿纳海姆(Anaheim)、卢呐(Lula)、瑞德(Reed)、奏呔喽(Zutano)、奎恩(Queen)、科勒斯尔菲(Criol Selva)、墨西哥凯特(Mexicana Canta)、瑞吉恩德尚(Region Dschang)、霍尔(Hall)、布斯(Booth)、彼得斯(Peterson)和科林森若德(Collinson Redn)品种。特别选择哈斯、福尔特、额廷格和培根品种,且更优选哈斯和福尔特品种。果实的重量从50g可变化至超过1kg。果实含有10至20%的种子,7至15%的外皮和65至80%的果肉。果皮的厚度、结构和颜色可变,从光滑的到粗糙的,通常是绿色的,但可变为棕色、微紫色至黑色。
果肉的香味和颜色可变,且其平均组成为:
表1:鳄梨果肉的组成;*Wei Wang,食品化学,122:1193-1198(2010)(Composition of avocado flesh;*Wei Wang,Food Chemistry,122:1193-1198(2010))
南美人普遍使用鳄梨果肉为头发增光。在皮肤局部涂抹鳄梨果肉也非常普遍,这由于它的抗氧化性和营养性的活性,与其含有的脂类(脂肪酸和非皂化物成分-维他命E)的性质有关。
果实,特别是它的果肉通常在热带家庭治疗中使用。果实尤其富含维他命A、B、C、D、E和K,并推荐用于糖尿病患者。果肉还可杀螨(及杀虫)、壮阳、滋补。在南美敷用以治疗疖和疔。
已被证实大量使用鳄梨对胆固醇水平具有影响。特别是食用7天富含鳄梨的饮食之后,高胆固醇血症患者可见其总胆固醇水平降低17%。这一实验还证实LDL胆固醇水平(坏)和甘油三酯减低了22%,且HDL胆固醇(好)增加了11%。它的单不饱和脂肪酸对心血管卫生保健极好并血液胆固醇(HDL)有好处。此外鳄梨是非常好的纤维(可溶的和不可溶的)和抗氧化剂的来源。
术语“多酚”是指在植物领域普遍存在的一类分子,特征是存在一个或多个酚核,特别含有下述亚类:
■酚酸(肉桂酸和苯甲酸);
■黄酮类,几乎所有的植物色素,决定了花、果实且有时为叶子的颜色。花青素属于这类成分(颜色为蓝色至紫色,经由红色);
■醌和蒽醌类及某种衍生缩合形式;和
■更复杂的聚合形式:没食子酸和鞣花酸衍生的水解单宁;茶素酸、OPC或前花青素醇类(proanthocyanidols)衍生的缩合单宁。
已知这些分子有多种生物活性(抗氧化、抗炎、抗菌)且在药物、美容和营养/食品补充剂领域中用作某些特定的功能性结构。
多酚广泛分布于很多科的高等植物中,因为它通常为这些植物生存之必须,即对抗多种外在伤害(紫外线、干旱、微生物等)。
在分布最广、使用最多的多酚中,可提及的多酚来自茶(山茶Camelliasinensis)、葡萄(Vitis vinifera)、可可(Theobroma cacao)。申请FR2 928 263描述了一种含有植物多酚(特别描述了苹果多酚)和植物糖类的组合物。得到的多酚为聚合多酚,特别是前花青素和原飞燕草素(prodelphinidins)。鳄梨未作为糖类的来源而被引证。
发明者发现富含多酚的鳄梨(Persea gratissima或americana)提取物具有美容用、皮肤病用、药物用和营养品用的特性,特别是美容用和皮肤病用的特性在以前从未被描述。特别是第一次将富含多酚的鳄梨提取物因由其具体的特性而被用于此处。
本发明的目的特别在于:
-富含多酚的鳄梨果实提取物,含有的多酚重量以没食子酸当量计,为获得的干燥提取物重量的至少10%,所述多酚优选为前花青素、咖啡酸及咖啡酸衍生物,其重量以没食子酸当量计,特别为多酚总重量的至少70%。特别是该提取物含有的多酚重量以没食子酸当量计为获得的干燥提取物重量的10至30%。在所述多酚中的前花青素、咖啡酸或咖啡酸的衍生物的重量以没食子酸当量计,为多酚总重量的至少80%。
前花青素优选自B-型前花青素二聚体、A-和B-型前花青素三聚体和A-和B-型前花青素四聚体组成的组。
在提取物中含有的多酚含有以没食子酸当量计为多酚总重量至少30%的前花青素。
在该提取物中含有的多酚优选含有咖啡酸及其衍生物,其重量比以没食子酸当量计特别为多酚总重量的至少30%。
该提取物优选进一步含有以重量比计,至少为干燥提取物总重量10%,优选10至60%的鳄梨糖,所述糖至少含有D-甘露庚酮糖和/或鳄梨糖醇。
该提取物最好得自鳄梨果实提取物,优选在温和条件下干燥并脱脂的鳄梨果实提取物。
在一个优选方式中,其由部分鳄梨果肉在水和/或醇和/或二元醇的和/或丙三醇的溶剂中由固液提取法获得。溶剂优选自水、乙醇、丙三醇或二醇类例如丙二醇,及其混合物例如二元混合物组成的组,相对于其它溶剂有0至100%比例的水。
-一种组合物含有本发明提取物作用活性剂以及,优选一种适宜的载体。特别是,该组合物为美容用、药物用、皮肤病学用或营养保健品用组合物。
该组合物进一步包含另一活性剂,特别选自润肤剂、保湿的活性剂、角化调节剂、角质软化剂、愈合剂和/或重组皮肤屏障剂、PPAR、RXR或LXR激动剂、皮脂调节剂、抗刺激和/或抗炎和/或润肤剂、抗氧化剂、抗老化剂、脱色或美白祛斑剂、着色剂、脂肪分解或脂肪生成抑制剂或抗蜂窝组织炎或减肥剂、有机或无机的防晒剂或(色素或微粒)过滤剂、抗真菌化合物、防腐剂、抗菌剂、益生元、益生菌、抗生素和免疫调节剂组成的组。
该组合物优选含有用于治疗粉刺的活性剂作为另一活性剂,特别选自含有5-α还原酶抑制剂、锌(以及葡糖酸锌、水杨酸锌盐和焦谷氨酸锌)、螺内酯、亚油酸、抗生素、过氧化苯甲酰、壬二酸、维生素PP、维生素B3、细胞周期蛋白、南瓜子的提取物、南瓜籽油和棕榈。
-本发明的提取物或组合物用作药物用、皮肤病学用或美容用组合物或作为功能性食品。特别用于预防和/或治疗皮肤和/或粘膜和/或附属器紊乱或病变,更特别用于预防和/或治疗过敏、炎症、刺激性反应或病变,或皮肤屏障或动态平衡的紊乱,或血管病,或用作脱色或愈合剂。
-一种包括施予本发明的组合物或提取物,以期改善皮肤和/或附属器和/或粘膜状况或外观的美容护理方法。
措辞“富含多酚的鳄梨提取物”是指通过能富集在鳄梨中潜在的多酚的方法获得的提取物,在此方法中,提取物含有的多酚重量以没食子酸当量计为干燥提取物重量的至少10%。本发明另一优选变化方式中,提取物含有的多酚重量以没食子酸当量计为获得的干燥提取物重量的10至30%,多酚的重量更优选10至20%。
在本发明提取物中干燥提取物的比例以重量计,在提取物总重量0.01至90%之间变化,优选0.5至50%,更优选0.5至15%,甚至更优选0.5至5%。
在提取物中含有的多酚含有前花青素、咖啡酸和咖啡酸衍生物,特别是酯化衍生物的重量比例以没食子酸当量计为多酚总重量的至少70%,优选至少80%,更优选至少90%,甚至更优选至少95%。
前花青素是儿茶素/表儿茶素的低聚物。儿茶素和表儿茶素分别是下述分子式(I)的(+)和(-)光学异构体。
前花青素优选B-型前花青素二聚物。B-1、B-2、B-3和B-4型前花青素是由(+)儿茶素和(-)表儿茶素两个单元通过C4-C8相连组成。B-5、B-6、B-7和B-8型前花青素是由(+)儿茶素和(-)表儿茶素两个单元通过C4-C6相连组成。
前花青素更优选A和B型前花青素三聚物。
前花青素更优选A和B型前花青素四聚物。
前花青素更优选前花青素的低聚体或多聚体(儿茶素和表儿茶素的单元数量>4)。
提取物中含有的多酚以没食子酸当量计优选含有多酚总重量至少30%,更优选至少50%重量的前花青素。
提取物中含有的多酚还优选含有咖啡酸及其衍生物的重量比以没食子酸当量计为多酚总重量中的至少20%,更优选至少30%重量比。
咖啡酸具有下述结构式(II)
咖啡酸及其衍生物,苯乙基咖啡酸酯(咖啡酸和2-苯乙基醇的酯)存在于多种植物中,特别在咖啡中大量存在,并因此得名。咖啡酸可以酯的形式存在,例如与奎尼酸形成绿原酸。在其它酯化形式中,可提及的是与酒石酸形成咖啡酰酒石酸(或咖啡酸)、咖啡酰莽草酸(与莽草酸形成)、咖啡酰苹果酸(与苹果酸形成),或与葡萄糖成酯(咖啡酰葡萄糖)或与腐胺形成酰胺(咖啡酰腐胺)。
其它多酚也可存在于本发明提取物中,但是其含量不多。它们的重量含量以没食子酸当量计优选少于多酚总重量的30%,更优选少于20%,甚至更优选少于10%,甚至更优选少于5%,甚至更优选少于2%。
本发明另一优选变化方式中,提取物含有至少10%,优选10至60%,更优选10至30%的鳄梨糖,特别是所述糖至少含有D-甘露庚酮糖和/或鳄梨糖醇(百分数以其重量占干燥提取物的重量计)。
在本发明的上下文中,术语“D-甘露庚酮糖”和“鳄梨糖醇”均包括其化学衍生物。
鳄梨糖主要是D-甘露庚酮糖、甘露庚酮糖、蔗糖、葡萄糖和果糖。也可发现其它的糖的痕迹,但是其重量含量少于鳄梨糖总重量的5%,优选少于2%。
在发明提取物中,鳄梨糖中D-甘露庚酮糖和/或鳄梨糖醇总的重量比优选为总糖重量含量的至少50%。更优选鳄梨糖中D-甘露庚酮糖和/或鳄梨糖醇总的重量比为总糖重量含量的50至98%,更优选55至95%,甚至更优选60至90%。
D-甘露庚酮糖与鳄梨糖醇的重量比优选在1∶10至10∶1变化。
本发明提取物优选含有以重量百分比计为干燥提取物总重量0至50%,更优选0至20%,甚至更优选0至10%重量的鳄梨脂类。
本发明提取物优选含有以重量百分含量计为干燥提取物总重量,0至60%,更优选1至30%,甚至更优选5至15%重量的鳄梨蛋白质类(Bradford含量测定)。
本发明提取物通过提取部分鳄梨果实,优选果肉和/或果皮而获得。更特别的是使用源自压榨干燥鳄梨果肉的残余油饼。更优选的是,所述果肉在液体提取之前进行干燥。
特别优选使用鳄梨果实(果肉和/或果皮),首先在温和条件下进行干燥,并再脱脂。已注意到在这样条件下通过多酚酶在干燥过程中失活,可确保选择性保护多酚(甚至得到的提取物中不含有多酚酶)。
优选,提取物是部分鳄梨果肉在水和/或醇和/或二元醇的(glycolic)和/或丙三醇的(glycerolic)溶剂中通过固-液提取法获得。果实部分优选自干燥和/或脱脂果肉(油饼)和/或果皮,更优选在温和条件下干燥之后脱脂的果肉。
溶剂优选自由水、乙醇、丙三醇或二元醇(glycol)例如丙二醇,及其混合物例如二元混合物组成的组,相对于其它溶剂中有0至100%比例的水。
基本上,使用的溶剂二元混合物是水和选自乙醇、丙三醇或丙二醇组成的组。
更优选将按重量0.1至50%(以鳄梨+溶剂总重量计)的鳄梨干燥部分放入提取溶剂中,且重量更优选10%。
在乙醇存在时,优选水中的乙醇比为30至70%,且优选含醇量为50至60%(百分比以在水和乙醇总重量中的乙醇重量计)。
在丙三醇存在时,优选丙三醇的浓度为40至90%,且优选为60至80%(百分比以在水和丙三醇总重量中的丙三醇重量计)。
在二元醇存在下,更优选丙二醇,优选水中的丙二醇比为40至80%,且优选含醇量为50至60%(百分比以在水和丙二醇总重量中的丙二醇重量计)。
提取温度优选在4至100℃,且优选在10至60℃,且更优选在15至30℃。
提取时间优选在30分钟至4小时内变化,更优选为30分钟至2小时。
这些不同的提取物可随后用超滤(例如截留10kDa)、透析过滤和/或纳米过滤(例如截留200Da)进行纯化,除去糖(具体包括C7鳄梨糖、甘露庚酮糖和鳄梨糖醇)以富集多酚。
由这些纯化步骤得到的提取物含有的多酚重量以没食子酸当量计,优选为干燥提取物重量的10至30%,多酚重量甚至更优选为10至20%。
由这些纯化步骤得到的提取物中的糖的重量含量优选为干燥提取物重量的5至20%。
在提取物中存在的糖重量优选含有以糖总重量计为20至60%的D-甘露庚酮糖和/或鳄梨糖醇,更优选30至60%的D-甘露庚酮糖和/或鳄梨糖醇。
获得的提取物可以液体形式提供,也可以用本领域技术人员已知的方法例如喷雾或冷冻干燥法来干燥,加入或不加入助剂例如糊精。
本发明目的还在于一种包括下述连续步骤的制备富含多酚提取物的方法:
(a)将鳄梨果实(优选果肉和/或果皮),更优选干燥脱脂果肉(油饼)在适宜溶剂中液相分散。
(b)接着将步骤(a)中获得的混合物在水和/或醇和/或二元醇的和/或丙三醇的溶剂中搅拌,更优选水和选自乙醇、丙三醇、二元醇(优选丙二醇)及其混合物组成的组的溶剂,优选水中这些溶剂比为60%。
(c)接着将步骤(b)中获得的提取物浓缩并随后过滤,或直接过滤。
(d)如果需要,将步骤(c)获得的提取物进行超滤和/或透析过滤和/或纳米过滤的步骤;
(e)步骤(c)或(d)之后,回收获得富含多酚的提取物;且
(f)选择性干燥步骤(e)中获得的提取物,加入助剂或不加。
提取物优选用作含有一种或多种适宜载体的美容用、药物用、皮肤病学用或营养保健品用组合物的活性剂。该组合物除了富含多酚的提取物之外还可进一步含有至少一种其它的活性物质。这种其它的物质可选自所有的物质及其下述功能等效物质。
其它的物质可特别选自典型用于皮肤病用、药物用、美容用或营养保健品用的活性剂,以及本领域技术人员公知的那些,例如润肤剂、保湿的活性剂、角化调节剂、角质软化剂、愈合剂和/或重组皮肤屏障剂、PPAR、RXR或LXR激动剂、皮脂调节剂、抗刺激和/或抗炎和/或润肤剂、抗氧化剂、抗老化剂、脱色或美白祛斑剂(hypopigmenting)、着色剂、脂肪分解或脂肪生成抑制剂或抗蜂窝组织炎或减肥剂、有机或无机的防晒剂或(色素或微粒)过滤剂、抗真菌化合物、防腐剂、抗菌剂、益生元、益生菌、抗生素和免疫调节剂。
更特别的是,可组合使用的愈合剂和/或重组皮肤屏障剂优选为泛醇(维生素B5)、阿拉伯半乳聚糖、氧化锌、神经酰胺、角鲨烷、胆固醇和磷脂。
可组合使用的皮脂调节剂,优选自5-α还原酶抑制剂,如锌和锌衍生物(其葡糖酸盐、水杨酸盐和焦谷氨酸)组成的组。
抗炎和/或抗刺激和/或润肤剂可以是阿拉伯半乳聚糖。
可以组合使用的防晒活性剂优选UVB和/或UVA过滤剂或防晒剂,例如本领域技术人员已知的矿物和/或有机屏障或过滤剂,本领域技术人员可根据需要的保护程度进行选择并调整浓度。
可组合使用的防腐剂,例如为通常用于化妆品或保健食品中,具有抗菌活性的分子(类防腐剂)如辛酸衍生物等,例如,辛酰基甘氨酸和甘油辛酸酯,己二醇,乙酰丙酸钠和铜和锌的衍生物(葡糖酸盐和PCA)。
与本发明提取物组合使用的推荐活性剂中,可提及的是植物提取物,特别是:
-植物油,例如大豆油和/或菜籽油,鳄梨油(WO2004/012496,WO2004/012752,WO2004/016106,WO2007/057439),羽扇豆油,或这些油的混合物优选白甜羽扇豆油(WO98/47479);
-油馏出液或动物或植物油的浓缩物,特别是向日葵,更优选葵花亚油酸浓缩物,例如葵花油浓缩的非皂化物(参见国际申请WO01/21150),由Laboratoires Expanscience出售,油浓缩的非皂化物,如鳄梨油、菜籽油,玉米油或棕榈油,有显著的保湿和/或润肤、愈合和/或皮肤屏障重组、抗炎和/或抗刺激和/或舒缓活性;
-植物或植物油的非皂化物,优选是可通过国际申请WO01/21605所述方法获得的鳄梨呋喃类鳄梨和/或大豆的非皂化物,更优选鳄梨呋喃非皂化物和大豆非皂化物的混合物,优选其各自比例约1/3-2/3(例如大豆非皂化物(例如据国际申请WO01/51596所述方法获得)、甾醇类非皂化物(典型的非皂化物,其中甾醇类、甲基甾醇类和三萜醇的重量比为非皂化物总重的20至95%,优选45-65%),植物甾醇类,甾醇类酯和维生素衍生物,有显著的愈合和/或皮肤屏障重建、抗老化或抗炎活性;
-植物氨基酸的肽类或混合物,特别是鳄梨肽(如在国际申请WO2005/105123所述的),羽扇豆肽(如根据申请WO2005/102259中所述方法获得的),藜麦肽(如在国际申请WO2008/080974中所述的),玛卡(maca)肽(如在国际申请中WO2004/112742所述的),发酵或非发酵的大豆肽,大米肽(如在国际申请WO2008/009709中所述的),有显著的保湿和/或润肤活性(牛油果),美白祛斑活性(羽扇豆,藜麦),愈合和/或的皮肤屏障重组活性(玛卡、藜麦,大豆),抗炎和/或抗刺激和/或舒缓活性(羽扇豆,藜麦),抗氧化活性(牛油果),抗老化活性(羽扇豆,玛卡)和着色活性(大米);
-植物糖,特别是鳄梨糖(如申请WO2005/115421中所述的),具有显著的美白祛斑、愈合和/或皮肤屏障重组,抗炎和/或抗刺激和/或舒缓的特性;
-鳄梨油酸丁酯(5alpha 5-α还原酶抑制剂(见WO01/52837和WO02/06205)通常调节被发现能增加痤疮、头皮屑的脂溢性分泌物;
-富含多酚提取物,更优选白花菜(Gynandropsis gynandra)(FR1 061 051)地上部分的提取物和玛卡叶的提取物(FR1061051)。
-羽扇豆醇(FR2 8228212,FR857596)显著用于促进愈合;
-羽扇豆总提取物(如在国际申请WO2005/102259中所描述的),特别适用于刺激的治疗;
-大叶金合欢(Acacia macrostachya)种子(FR0958525)、玛卡叶(FR1061047)、五味子(Schisandra sphenanthera)种子(FR250955343和0955344FR)和豇豆(Vigna unguiculata)种子(FR0958529)的提取物。
在这些与本发明提取物推荐合用的活性剂中,可提及的是噁唑啉,特别是选自2-十一烷基-4-羟甲基-4-甲基-1,3-噁唑啉,2-十一烷基-4,4-二甲基-1,3-噁唑啉,(E)-4,4二甲基-2-十七碳基-8-烯基-1,3-噁唑啉,4-羟甲基-4-甲基-2-十七烷基-1,3-噁唑啉,(E)-4-羟甲基-4-甲基-2-十七碳基-8-烯基-1,3-噁唑啉,2-十一烷基-4-乙基-4-羟甲基-1,3-噁唑啉组成的组,优选2-十一烷基-4,4-二甲基-1,3-噁唑啉(OX-100或WO2004050052,WO2004050079,WO2004112741)。特别用其消炎和/或抗刺激和/或舒缓、抗氧化、脱色、免疫调节的活性。
所有这些组合物中除了富含多酚的鳄梨提取物之外含有至少一种其它的活性物质,且可包括两种、三种、四种或多种的上述活性物质。
本发明组合物可配制成多种形式适用于局部给药,适用于口服、直肠、阴道、鼻、耳或支气管给药,以及用于肠胃外给药。
有关第一个的变化方式,适于局部给药的多种制剂特别包括霜剂、乳液、乳、润发油、洗液、油、水或水-醇或二元醇的溶液、粉剂、贴剂、喷雾剂、洗发水、涂剂(varnishes)或任何其它的外用产品。
有关第二个的变化方式,适于口服给药的多种制剂中,富含多酚的鳄梨提取物与营养补充剂或者营养组合物混合。在本发明的上下文中,营养补充剂可以富含多酚的鳄梨提取物的形式,或硬或软的植物胶囊或胶囊的形式提供。可以含有以富含多酚的鳄梨提取物计为10~100%的所述营养补充剂
本发明组合物可直接且未经其它的修饰,通过例如搅拌、灌输、注入、混合、吸收、捏合和喷涂技术,混入到营养制品、减肥产品,特别是超蛋白(hyper-protein)制品或饮料中。
本发明混合物或组合物的给药方式、剂量和植物制剂形式可根据在药物治疗,特别是皮肤病用、美容用或兽用治疗中确立的适于患者或动物的,通常考虑的标准,例如患者或动物的年龄或体重、患者或动物总体状态的严重性、治疗耐受量、需注意的副作用和皮肤类型等而确定。根据所期望的给药类型,本发明的活性组合物和/或混合物可进一步含有至少一种药学上可接受的载体,特别是皮肤病学可接受的载体或美容用或营养品用可接受载体。有关第一种的变化方式,使用适于体外局部给药的载体。本发明组合物还可进一步含有至少一种药用或美容用的本领域技术人员已知的助剂,选自增稠剂、防腐剂、香料、着色剂、化学或矿物过滤剂、保湿剂、热水等。
具有所述特征含有富含多酚的鳄梨提取物的组合物特别用于美容、药用或皮肤病。组合物优选配制成适于局部给药的形式。
本发明的目的还在于使用富含多酚的鳄梨提取物制备美容用、药用、皮肤病用或营养用组合物或功能性食品。
优选本发明的组合物或提取物用于预防和/或治疗皮肤、粘膜或附属器的紊乱或病变。
特别是,本发明的组合物或提取物旨在预防和/或治疗过敏、炎症、刺激性反应或病变,或皮肤、附属器(头发和指甲)和/或粘膜(牙龈、牙周、生殖器粘膜)屏障或动态平衡的紊乱,不论是否不成熟的、正常的或成熟的/老化的。
措辞“皮肤、附属器和/或粘膜屏障的紊乱”是指介入皮肤外层水平的紊乱。
措辞“皮肤、附属器和/或粘膜动态平衡的紊乱”是指由细胞更新或平衡过程引起的紊乱,例如银屑病、过敏性皮炎、尿布疹、皮肤干燥(干燥症)、皮肤脱水和光敏性皮肤病。
优选本发明的组合物或提取物用于预防和/或治疗如下的反应、紊乱或病变:
-皮肤、如酒渣鼻或红斑(erythrocouperosis)、银屑病、血管病、尿布疹、特应性皮炎、湿疹、接触性皮炎、刺激性皮炎、遗传过敏性皮炎、脂溢性皮炎(乳乙痂)、敏感性皮肤、反应性皮肤、瘙痒、皮肤干燥(干燥症)、皮肤脱水、皮肤发红、皮肤红斑、老化或光老化皮肤、光敏性皮肤病、色素沉着性皮肤(黄褐斑、炎症后的色素沉着)、皮肤蜂窝组织炎、皮肤松弛、妊娠纹、皮屑、皲裂、咬伤、破裂(特别是乳房的)、晒伤、由所有类型的射线、受到化学、物理(例如孕妇的张应力)、细菌、真菌或病毒、寄生虫(虱、疥疮、癣、螨虫、皮肤癣菌)或放射性物质或先天免疫(抗菌肽)或获得性免疫(细胞、体液、细胞因子)缺陷的刺激所引起的炎症,和/或
-粘膜如牙龈和牙周的牙龈炎(牙龈敏感的新生儿,卫生问题,由于使用烟草或其他产品引起),齿槽病或男性或女性生殖器的生殖器粘膜呈现外部或内部的刺激,和/或
-上皮附属器,例如指甲(易断、脆性指甲等)和头发(脱发、头皮屑、多毛症、脂溢性皮炎、毛囊炎),无论是不成熟的、正常的或成熟,特别是出现的头皮紊乱,例如雄激素、急性的、局部的、瘢痕和先天性的、婴儿枕部和簇状的脱发(或斑秃)、由于化疗/放疗或静止期引起的脱发、再生期脱发、毛囊萎缩、拔毛发癣、癣或油性或干性的头屑。
本发明的组合物或提取物还优选用于预防和/或治疗血管病,且优选通过减少黑素和/或抑制酪氨酸酶用于色素沉着不足,或作为愈合剂。
本发明还涉及一种为了改善皮肤、体表性生长或粘膜状态或外观的美容护理方法,包括施予本发明美容用组合物或提取物。
本发明美容方法的实施例中,所述皮肤和/或附属器和/或粘膜优选那些敏感的,被环境(紫外线、污染)刺激或损伤的,特别是敏感性皮肤。
本发明的美容方法,其特征还在于该组合物或提取物用作保湿性产品,或作为时间或光诱导的抗老化产品,预防衰老和光诱导的老化,或作为减肥和/或抗蜂窝织炎的产品,或作为抗老化或抗老祛斑的产品。
措辞“保湿性产品”是指能预防和/或治疗皮肤、附属器和/粘膜的屏障或动态平衡的紊乱的产品。
措辞“抗老祛斑产品”是指能减少皮肤和/或附属器和/或粘膜的色素沉着斑的产品。
措辞“减肥和/或抗蜂窝织炎的产品”是指能改善皮肤的紧致度、弹性或张性,和/或对抗脂肪组织的堆积和皮肤蜂窝织炎的产品。
实施例1
将干燥并脱脂的鳄梨果肉(油饼)在室温下,搅拌分散于浓度为10%、乙醇/水为60/40(w/w)的混合液中1个小时。通过过滤、沉降或离心法将残余的干物质与液相分离,并且为了得到透明溶液,使用适宜孔径的过滤器过滤获得液相。获得的提取物具有下述特性:
■干燥提取物:2.56%
■总糖(葡萄糖、果糖、甘露庚酮糖、鳄梨糖醇;HPLC):19.5%/干燥物
■总多酚(Folin-Ciocalteu;没食子酸当量):14%/干燥物
■蛋白质(Bradford分析法):6.25%/干燥物
该提取物具有抗辐射活性,“管内”(in tubo)抗-DPPH活性,可测定其最大半数抑制浓度(IC50)且为干燥提取物的111μg,这代表10.6μg的多酚在反应介质中。
实施例2
将干燥并脱脂的鳄梨果肉(油饼)在室温下,搅拌分散于浓度为10%、丙三醇/水为60/40(w/w)的混合液中1个小时。通过过滤、沉降或离心法将残余的干物质与液相分离,并且为了得到透明溶液,使用适宜孔径的过滤器过滤获得液相。获得的提取物具有下述特性:
■干燥提取物:3.45%
■总糖(葡萄糖、果糖、甘露庚酮糖、鳄梨糖醇;HPLC):19%/干燥物
■总多酚(Folin-Ciocalteu;没食子酸当量):12%/干燥物
■蛋白质(Bradford分析法):9%/干燥物。
该提取物具有抗辐射活性,“管内”抗-DPPH活性,可测定其最大半数抑制浓度(IC50)且为干燥提取物的84μg,这代表有11.85μg的多酚在反应介质中。
实施例3
将干燥并脱脂的鳄梨果肉(油饼)在室温下,搅拌分散于浓度为10%、丙二醇/水为60/40(w/w)的混合液中1个小时。通过过滤、沉降或离心法将残余的干物质与液相分离,并且为了得到透明溶液,使用适宜孔径的过滤器过滤获得液相。获得的提取物具有下述特性:
■干燥提取物:2.74%
■总糖(葡萄糖、果糖、甘露庚酮糖、鳄梨糖醇;HPLC):22%/干燥物
■总多酚(Folin-Ciocalteu;没食子酸当量):16%/干燥物
■蛋白质(Bradford分析法):7%/干燥物。
该提取物具有抗辐射活性,“管内”抗-DPPH活性,可测定其最大半数抑制浓度(IC50)且为干燥提取物的119.5μg,这代表18.5μg的多酚在反应介质中。
实施例4:局部给药组合物
本发明存在下述多种用于局部给药的组合物。鳄梨(Persea gratissima和americana)富含多酚的提取物可与多种美容用产品,例如清洁水、水包油乳剂、油包水乳剂、油类、乳、乳液、洗发水、泡腾产品和喷雾剂混合,其组成如下:
敏感性皮肤的清洁水
商品或INCl名称 | % |
辛酰甘氨酸 | 0-1% |
钠碱液 | 0-1% |
螯合剂 | 0-1% |
丁二醇 | 1-5% |
β-胡萝卜素 | 0-2% |
富含多酚的鳄梨提取物 | 0.01-10% |
防腐剂 | 0-1% |
PEG-32 | 1-5% |
PEG-7棕榈椰油酸 | 1-5% |
葡萄糖酸锌 | 0-1% |
柠檬酸 | 0-1% |
纯水 | 适量至100% |
香精 | 0-1% |
泊洛沙姆(Poloxamer)184 | 1-5% |
抗老化乳液
商品或INCl名称 | % |
液状异链烷烃 | 5-20% |
硬脂酸异鲸蜡醇 | 5-20% |
Al-Mg羟基硬脂酸 | 5-20% |
Abil WE09 | 1-5% |
甘油 | 1-5% |
凡士林油 | 1-5% |
微粉化氧化锌 | 1-5% |
丁二醇 | 1-5% |
维生素A | 0-1% |
维生素C | 0-5% |
富含多酚的鳄梨提取物 | 0.01-10% |
异壬酸异壬酯 | 1-5% |
蜂蜡 | 1-5% |
酒石酸钠 | 1-5% |
氯化钠 | 0-5% |
甘氨酸 | 1-5% |
防腐剂 | 0-1% |
胆固醇 | 0-1% |
植物鞘氨醇(Phytosphingosin) | 0-1% |
酒石酸 | 0-1% |
纯水 | 适量至100% |
干燥、特应性皮肤乳
原料/商品或INCl名称 | % |
甜扁桃仁油 | 1-5% |
玉米油 | 1-5% |
硬脂酸 | 1-5% |
C16~C18鲸蜡醇 | 0-1% |
消泡剂70414 | 0-1% |
月桂醇110E | 1-5% |
PEG300单月桂酸酯 | 0-1% |
甘油单油酸酯 | 0-1% |
单硬脂酸甘油酯 | 1-5% |
维生素B12 | 0-5% |
富含多酚的鳄梨提取物 | 0.1-10% |
防腐剂 | 0-1% |
柠檬酸 | 0-1% |
柠檬酸三钠 | 0-1% |
纯水 | 适量至100% |
香料 | 0-1% |
花生油 | 1-5% |
氢化棕榈油 | 1-5% |
清洁霜
原料/商品或INCl名称 | % |
纯水 | 适量至100% |
Arlatone | 10-30% |
椰油基-糖苷(Cocoglucoside) | 5-20% |
羟丙基瓜尔胶 | 1-5% |
辛酰甘氨酸 | 0-2% |
防腐剂 | 0-2% |
香料 | 0-1% |
柠檬酸 | 0-1% |
PCA锌 | 0-1% |
富含多酚的鳄梨提取物 | 0.01-10% |
去屑洗发水
原料/商品或INCl名称 | % |
纯水 | 适量至100% |
月桂酰两性基乙酸(Lauroamphoacetate) | 5-20% |
椰油基-糖苷 | 5-20% |
PEG6000二硬脂酸酯 | 1-5% |
防腐剂 | 0-2% |
维生素F | 0-5% |
吡罗克酮乙醇胺(Piroctone olamine) | 0-2% |
富含多酚的鳄梨提取物 | 0.01-10% |
吡啶硫酮锌 | 0-1% |
pH调节剂 | 0-1% |
螯合剂 | 0-1% |
香料 | 0-1% |
实施例5:口服给药组合物
将鳄梨提取物加入口服组合物中,在组合物中能够每日施予50至200mg的富含多酚的鳄梨提取物。
1、软胶囊形式的抗妊娠纹组合物
该组合物每天以4至6粒500mg的胶囊施予。
2、抗脱发片剂
该组合物每天以5至8片的片剂施予。
3、减肥药粉棒的实施例
该组合物每天施予两次。
实施例6:生物活性
1.抗炎作用
a、对角蛋白细胞的抗炎作用
皮肤中,角蛋白细胞是首先参与应答环境攻击的炎性反应的细胞之一。
该“被攻击的”角蛋白细胞随后释放细胞因子,引起包括免疫系统在内的级联反应。
材料和方法:
将人角化细胞(NCTC-2544细胞系)与经富集多酚的鳄梨提取物(AV)在浓度0.005%和0.01%(活性物质的W/V)或抗炎剂参照分子(10-7M地塞米松、10-6M吲哚美辛)预培养或不预培养(对照)24小时。随后始终在AV或参照品存在下将细胞用0.1μg/ml的十四酰佛波乙酸酯(PMA)处理24小时。
处理后,在培养液的上清液通过EL1SA测定分泌的白细胞介素8(IL8)和前列腺素E2(PGE2)量。
该结果用学生氏T-检验(Student’s t-test)统计分析。
结果和结论:
AV强烈并显著抑制了角蛋白细胞中PMA刺激的炎性介质IL8和PGE2的产生。
AV提取物因此具有抗炎活性。
表1角蛋白细胞产生的IL8和PGE2
b.对中性白细胞生成白三烯B4的抑制
白三烯B4(LTB4)是花生四烯酸通路引起的脂质炎性介质。
LTB4通过人类嗜中性粒细胞由5-脂氧合酶催化而被大量产生并释放,它在皮肤炎症反应的发展中扮演重要角色。
材料和方法:
人类中性白细胞在经富集多酚的鳄梨提取物(AV)浓度为0.005%、0.01%和0.1%(活性物质的W/V)的条件下预培养15分钟。
随后加入1mg/ml酵母多糖刺激细胞。
培养10分钟后,用ELISA法测定细胞上清液中细胞释放的白三烯B4(LTB4)。
结果用学生氏T检验进行统计分析。
结果和结论:
AV显著抑制了中性白细胞由酵母多糖诱导的LTB4的产生(表2)。
因此,AV提取物可调节嗜中性粒细胞和LTB4诱导的炎症。
表2中性白细胞产生的白三烯B4
C对组胺释放的抑制
肥大细胞在过敏和炎症反应中扮演了重要角色。在人体内,其广泛分布在结缔组织、例如皮肤中。血清肥大细胞是局部炎症应答的前哨细胞。物质P,一种神经肽,通过诱导储存颗粒中形成的组胺的快速释放而作用于肥大细胞;这种神经源性炎症的机制包含于多种皮肤病理中。
材料和方法:
肥大细胞在经富集多酚的鳄梨提取物(AV)浓度为0.01%(活性物质的W/V)或10mM钙(组胺释放抑制剂的参照组)的条件下预培养30分钟。
肥大细胞随后用10μM物质P刺激15分钟。培养后,用ELISA法测定组胺的释放。
结果用学生氏T检验进行统计分析。
结果和结论:
AV显著抑制了物质P刺激的肥大细胞的组胺的释放(表3)。
该AV提取物可显著调节组胺相关的神经源性炎症。
表3肥大细胞释放的组胺
2.脱色作用
AV提取物的脱色作用在两个不同的模型中进行研究:评价黑素细胞中黑素的产生以及评价参与黑素形成的关键酶——酪氨酸酶的酶的活性。
a、黑素生成的抑制
材料和方法:
将正常人类表皮的黑素细胞在10-7M NDP-MSH(α-MSH黑素生成的类诱导剂)和经富集多酚的鳄梨提取物(AV)浓度为0.001%和0.005%(活性物质的W/V)或0.25mM曲酸(参照)的存在下培养。
培养240小时后,从细胞提取和色素并用分光光度法测定。
结果用学生氏T检验进行统计分析。
结果和结论:
AV显著抑制了NDP-MSH刺激黑素细胞而产生的黑素(表4)。
因此AV具有脱色作用。
表4黑素细胞产生的黑素
b、酪氨酸酶活性的抑制
材料和方法:
经富集多酚的鳄梨提取物(AV)和多种浓度的曲酸(参照)在低温下,在提取自人黑素细胞的酪氨酸酶的存在下,预培养10分钟。
随后加入酶底物——2mM L-DOPA
在37℃培养1小时后,通过分光光度法评价酶的活性
结果用学生氏T检验进行统计分析。
结果和结论:
AV显著抑制了酪氨酸酶的酶活性(表5)。该结果证实了该提取物的脱色作用。
表5人酪氨酸酶活性
3.愈合作用:刺激表皮细胞再生的标志物
创伤诱导的瘢痕形成机制包括表皮修复再生的过程。
皮肤表皮细胞再生包括有组织的角蛋白细胞的再生、帕维曼托斯(pavimentous)、分层和角化覆盖伤口的上皮细胞以及保护屏障的重建。
表皮细胞再生机制通过三个步骤进行:角蛋白细胞的迁移、增生和表皮的成熟。
研究AV提取物对表皮细胞再生过程中参与角蛋白细胞迁移步骤的标志物、层粘连蛋白5和基质金属蛋白酶9(MMP9)的基因表达。
材料和方法:
正常人类角蛋白细胞在经富集多酚的鳄梨提取物(AV)浓度为0.001%和0.005%(活性物质的w/v)或5ng/ml TGFp(参照)的存在下培养48小时。
通过实时RT-PCR研究MMP9和层粘连蛋白5(亚基γ2)的基因表达。
结果用单因素方差分析法并用邓奈特检验(Dunnett’s test)进行统计分析:ns(不显著)p>0.05;*p<0.05;***p<0.001.
结果和结论:
AV显著增加了角蛋白细胞迁移标志物的表达(表6)
该提取物因而具有激发表皮再生的作用,促进修复、提前愈合的作用。
表6角蛋白细胞迁移标志物的基因表达(相对量)
Claims (15)
1.一种富含多酚的鳄梨果实提取物,含有相对于获得的干燥提取物、以没食子酸当量计至少10%优选10至30%重量的多酚,所述多酚优选含有相对于多酚的总重量、以没食子酸当量计特别地为至少70%重量的前花青素、咖啡酸及咖啡酸衍生物。
2.如权利要求1的提取物,其特征在于所述多酚含有相对于多酚的总重量、以没食子酸当量计至少80%重量的前花青素、咖啡酸或咖啡酸衍生物,所述前花青素优选自B-型前花青素二聚体、A-和B-型前花青素三聚体和A-和B-型前花青素四聚体组成的组。
3.如权利要求1或2的提取物,其特征在于在该提取物中含有的多酚含有相对于多酚的总重量、以没食子酸当量计至少30%的前花青素。
4.如上述任一权利要求的提取物,其特征在于在该提取物中含有的多酚含有相对于多酚的总重量、以没食子酸当量计至少30%重量的咖啡酸及其衍生物。
5.如上述任一权利要求的提取物,其特征在于该提取物进一步含有相对于干燥提取物的重量,重量百分比为至少10%,优选10至60%的鳄梨糖,所述鳄梨糖至少含有D-甘露庚酮糖和/或鳄梨糖醇
6.如上述任一权利要求的提取物,其特征在于该提取物通过提取鳄梨果实而获得,优选通过提取首先在温和条件下被干燥,随后经脱脂的鳄梨果实。
7.如权利要求1~6任一提取物,其特征在于在水和/或醇和/或二元醇的和/或丙三醇的溶剂中通过固液提取法提取部分鳄梨果实从而获得该提取物。
8.如权利要求7的提取物,其特征在于溶剂选自水、乙醇、丙三醇或例如丙二醇的二元醇或其混合物组成的组,优选二元混合物,其中在该混合物中,相对于其它溶剂,水的比例为0至100%。
9.一种组合物,含有作为活性剂的权利要求1至8任一所述提取物和合适的载体,其特征在于该组合物为美容用、药物用、皮肤病用或营养品用组合物。
10.如权利要求9的组合物,进一步含有另一活性剂,特别选自由润肤剂、保湿的活性剂、角化调节剂、角质软化剂、愈合剂和/或重组皮肤屏障剂、PPAR、RXR或LXR激动剂、皮脂调节剂、抗刺激和/或抗炎和/或润肤剂、抗氧化剂、抗老化剂、脱色或美白祛斑剂、着色剂、脂肪分解或脂肪生成抑制剂或抗蜂窝组织炎或减肥剂、有机或无机的防晒剂或(色素或微粒)过滤剂、抗真菌化合物、防腐剂、抗菌剂、益生元、益生菌、抗生素和免疫调节剂组成的组。
11.如权利要求9或权利要求10的组合物,其特征在于另一活性剂选自:
愈合剂和/或和/或重组皮肤屏障剂,优选为泛醇、阿拉伯半乳聚糖、氧化锌、神经酰胺、胆固醇、角鲨烷和磷脂;
皮脂调节剂,优选自5-α还原酶抑制剂和锌衍生物;
抗炎和/或抗刺激和/或润肤剂,优选阿拉伯半乳聚糖;
美白祛斑或脱色剂,优选N-十一碳烯-L-苯丙氨酸;
有机或无机的防晒剂或过滤剂,优选UVB和/或UVA防晒剂和过滤剂;以及
防腐剂,优选自辛酰基甘氨酸、甘油辛酸酯和己二醇。
12.如权利要求9至11任一的组合物,进一步含有至少一种其它活性剂,选自:
植物油,优选大豆油、菜籽油、鳄梨油、羽扇豆油或这些油的混合物,优选白甜羽扇豆油;
油馏出液或动物或植物油的浓缩物,优选向日葵、鳄梨、油菜籽、大米或棕榈的,且优选在非皂化物中浓缩的浓缩物;
植物或植物油的非皂化物,优选鳄梨非皂化物、大豆非皂化物或其混合物,优选鳄梨呋喃类,且优选鳄梨呋喃非皂化物和大豆非皂化物各自配比约为1/3-2/3的混合物、甾醇类非皂化物、植物甾醇类、甾醇的酯及维生素衍生物;
植物氨基酸的肽类或混合物,优选是鳄梨肽、羽扇豆肽、藜麦肽、玛卡肽、发酵或非发酵的大豆肽、大米肽;
植物糖类,优选鳄梨糖;
鳄梨油酸丁酯;
富含多酚的提取物,优选白花菜地上部分的提取物和玛卡叶的提取物;
羽扇豆醇;
羽扇豆总提取物;
大叶金合欢种子提取物、玛卡叶提取物、五味子种子提取物和豇豆种子的提取物;
噁唑啉类,优选2-十一烷基-4-羟甲基-4-甲基-1,3-噁唑啉、2-十一烷基-4,4-二甲基-1,3-噁唑啉、(E)-4,4-二甲基-2-十七碳基-8-烯基-1,3-噁唑啉、4-羟甲基-4-甲基-2-十七烷基-1,3-噁唑啉、(E)-4-羟甲基-4-甲基-2-十七碳基-8-烯基-1,3-噁唑啉、2-十一烷基-4-乙基-4-羟甲基-1,3-噁唑啉和2-十一烷基-4,4-二甲基-1,3-噁唑啉及其混合物。
13.权利要求9至12任一的组合物,其特征在于将该组合物配制成经局部或口服途径给药。
14.如权利要求9至13任一的组合物或权利要求1至8任一定义的提取物,被用于预防和/或治疗皮肤和/或粘膜和/或附属器的紊乱或病变,优选过敏、炎症或刺激反应或皮肤屏障或角化的病变或紊乱或血管病,或用作脱色和愈合剂。
15.一种美容护理方法,包括施予如权利要求9至13任一所述的美容用组合物或权利要求1至8任一定义的提取物,用于皮肤、附属器和/或粘膜,特别是敏感皮肤,以期改善其状态或外观,特别是为了促进其水合,或改善皮肤的紧致度、弹性或张性并防止脂肪组织的堆积及皮肤的蜂窝织炎,或减少色斑,或预防和/或治疗老化。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1061055 | 2010-12-22 | ||
FR1061055A FR2969496B1 (fr) | 2010-12-22 | 2010-12-22 | Extrait de pulpe et/ou de peau d'avocat riche en polyphenols et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant |
PCT/EP2011/073832 WO2012085224A1 (fr) | 2010-12-22 | 2011-12-22 | Extrait de pulpe et/ou de peau d'avocat riche en polyphenols et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103347528A true CN103347528A (zh) | 2013-10-09 |
CN103347528B CN103347528B (zh) | 2015-04-22 |
Family
ID=44246374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180062296.4A Active CN103347528B (zh) | 2010-12-22 | 2011-12-22 | 富含多酚的鳄梨果肉和/或果皮提取物及含有它的美容用、皮肤病用和营养品用组合物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20130183255A1 (zh) |
EP (1) | EP2654766B1 (zh) |
KR (5) | KR20180125612A (zh) |
CN (1) | CN103347528B (zh) |
BR (1) | BR112013015593A2 (zh) |
CA (1) | CA2821876A1 (zh) |
ES (1) | ES2704665T3 (zh) |
FR (1) | FR2969496B1 (zh) |
WO (1) | WO2012085224A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104546522A (zh) * | 2014-12-18 | 2015-04-29 | 广东雅威生物科技有限公司 | 具有高效广谱抑菌能力的组合物及其在化妆品中的应用 |
CN107496290A (zh) * | 2017-08-31 | 2017-12-22 | 浙江大学 | 一种提取米糠多酚的方法及应用 |
CN107714629A (zh) * | 2017-12-08 | 2018-02-23 | 林燕 | 一种含有牛油果提取物的化妆笔笔油的制备方法 |
CN107847401A (zh) * | 2015-05-13 | 2018-03-27 | 缪斯化妆品株式会社 | 防脱发及生发组合物 |
CN107927786A (zh) * | 2017-12-28 | 2018-04-20 | 广西南宁桂尔创环保科技有限公司 | 一种从牛油果中提取多酚的方法 |
CN111450107A (zh) * | 2019-01-22 | 2020-07-28 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 落新妇苷有机酸组合物在治疗银屑病中的应用 |
CN112074326A (zh) * | 2018-04-12 | 2020-12-11 | 化工产品开发公司Seppic | 基于多咖啡酰基奎宁酸的新型组合物、其化妆品用途和包含其的化妆品组合物 |
CN112438918A (zh) * | 2019-08-30 | 2021-03-05 | 广东丸美生物技术股份有限公司 | 一种牛油果提取物及其制备方法和在抗衰老化妆品中的应用 |
CN113243443A (zh) * | 2021-05-10 | 2021-08-13 | 普洱丰华联合实业发展有限责任公司 | 一种牛油果咖啡及其制作方法 |
CN116568157A (zh) * | 2020-09-18 | 2023-08-08 | 佩滕集团有限公司 | 发酵鳄梨颗粒及包含其的食品补充剂 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
AU2006253007B2 (en) | 2005-05-31 | 2012-12-20 | Alimentary Health Ltd | Feline probiotic Bifidobacteria |
AU2006253006B8 (en) | 2005-05-31 | 2011-09-15 | Alimentary Health Ltd | Feline probiotic Lactobacilli |
JP5799299B2 (ja) | 2007-02-01 | 2015-10-21 | ザ・アイムス・カンパニーThe Iams Company | ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法 |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
FR3001889B1 (fr) * | 2013-02-11 | 2021-02-12 | Expanscience Lab | Utilisation d'une composition comprenant un perseose d'avocat dans la protection des cellules souches epidermiques . |
CN105101938A (zh) * | 2013-04-02 | 2015-11-25 | 气体产品与化学公司 | 用于个人护理产品的递送系统的组合物 |
US20140349002A1 (en) * | 2013-05-23 | 2014-11-27 | The Iams Company | Ingestible Compositions Containing Criollo Avocado Component |
DE102013223790A1 (de) * | 2013-11-21 | 2015-05-21 | Henkel Ag & Co. Kgaa | Verwendung kosmetischer Zusammensetzungen für die Inaktivierung und/oder Eliminierung von Hautmilben |
CN109996532A (zh) | 2016-10-04 | 2019-07-09 | 玫琳凯有限公司 | 用于处理萎缩纹的方法和组合物 |
CN107550748B (zh) * | 2017-08-31 | 2024-01-30 | 曾庆明 | 含金黄色葡萄球菌b型肠毒素蛋白和原花青素的抛光膏及制备与应用 |
CN112218616A (zh) | 2018-03-23 | 2021-01-12 | 玫琳凯有限公司 | 局部用组合物和方法 |
EP3574899A1 (en) * | 2018-05-28 | 2019-12-04 | Université de Bourgogne | Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses |
KR102068482B1 (ko) * | 2018-06-01 | 2020-01-21 | 대봉엘에스 주식회사 | 아보카도 및 상백피 복합 추출물을 포함하는 화장료 조성물 |
WO2020010171A1 (en) * | 2018-07-06 | 2020-01-09 | Elastogenesis, Llc | Dermal compositions and methods of use |
KR102134663B1 (ko) * | 2018-12-06 | 2020-07-16 | 자이글주식회사 | 산소를 포함하는 기능성 화장료 조성물 |
WO2020123306A1 (en) | 2018-12-14 | 2020-06-18 | Mary Kay Inc. | Cosmetic compositions |
FR3098405B1 (fr) * | 2019-07-12 | 2021-06-25 | Expanscience Lab | Composition comprenant des polyphénols de graines de passiflore, des peptides d’avocat et un extrait d’hamamélis et utilisation pour traiter et/ou prévenir les vergetures |
ES2841474B2 (es) * | 2020-01-08 | 2022-01-24 | Univ Valladolid | Composicion nutraceutica que consiste en un polifenol en solucion glicolica, metodo de obtencion y su uso terapeutico |
CN112826786A (zh) * | 2020-12-31 | 2021-05-25 | 国润生物科技(深圳)有限公司 | 一种靶向修复疤痕织网构建组合物及其应用 |
CN114391594A (zh) * | 2022-02-21 | 2022-04-26 | 中国科学院昆明植物研究所 | 一种鳄梨果皮发酵茶及其提取物与其制备方法与应用 |
FR3143977A1 (fr) * | 2022-12-21 | 2024-06-28 | Laboratoires Expanscience | Insaponifiables d'avocat-malassezia |
CN117618527A (zh) * | 2023-12-04 | 2024-03-01 | 山东益衡元健康科技有限公司 | 一种改善雄性激素水平和雄性性能力的组合物、制备方法及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1856293A (zh) * | 2003-09-23 | 2006-11-01 | 奥里金生物医学股份有限公司 | 多酚的无水局部用制剂 |
CN101711158A (zh) * | 2007-02-01 | 2010-05-19 | 爱默思公司 | 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR958525A (zh) | 1950-03-13 | |||
FR955343A (zh) | 1950-01-14 | |||
FR958529A (zh) | 1950-03-13 | |||
FR955344A (zh) | 1941-03-29 | 1950-01-14 | ||
FR1061051A (fr) | 1951-07-31 | 1954-04-08 | Heinrich Lanz Ag | Procédé pour la fabrication de moissonneuses, notamment de moissonneuses-lieuses de divers types |
FR1061047A (fr) | 1952-07-28 | 1954-04-08 | Aluminium Francais | Radiateur à ailettes |
FR2762512B1 (fr) | 1997-04-24 | 2000-10-13 | Pharmascience Lab | Compositions a base d'huile de lupin, notamment a base d'huile de lupin et d'huile de germe de ble et leur utilisation en cosmetologie, en pharmacie et en tant que complement alimentaire |
FR2798591B1 (fr) | 1999-09-22 | 2001-10-26 | Pharmascience Lab | Utilisation d'un produit d'huile vegetale pour augmenter la synthese des lipides cutanes en cosmetique, pharmacie ou dermatologie et en tant qu'additif alimentaire |
FR2798667B1 (fr) | 1999-09-22 | 2001-12-21 | Pharmascience Lab | Procede d'extraction des composes furaniques et alcools gras polyhydroxyles de l'avocat, composition a base de et utilisation de ces composes en therapeutique, cosmetique et alimentaire |
FR2803749B1 (fr) | 2000-01-18 | 2006-09-22 | Pharmascience Lab | Utilisation d'au moins un ester gras pour la preparation d'une composition destinee a inhiber l'activite de la 5 alpha-reductase, en pharmacie notamment en dermatologie, en cosmetique et en tant qu'additif alimentaire |
US6610320B2 (en) * | 2000-04-14 | 2003-08-26 | Mars, Incorporated | Compositions and methods for improving vascular health |
JP4589483B2 (ja) * | 2000-05-12 | 2010-12-01 | 花王株式会社 | ニキビ予防治療剤 |
FR2811984B1 (fr) | 2000-07-19 | 2004-02-06 | Pharmascience Lab | Procede de preparation d'un ester de corps gras et son utilisation dans les domaines pharmaceutique, cosmetique ou alimentaire |
FR2822821B1 (fr) | 2001-04-03 | 2004-05-07 | Pharmascience Lab | Extrait de coques de graines de lupin contenant du lupeol, en particulier extrait riche en lupeol et son procede de preparation |
US6994875B2 (en) | 2002-07-29 | 2006-02-07 | Laboratoires Expanscience | Process for obtaining a furan lipid-rich unsaponifiable material from avocado |
CA2493981C (fr) | 2002-07-30 | 2012-06-26 | Laboratoires Expanscience | Procede d'obtention d'un extrait de feuilles d'avocatier riche en lipides furaniques |
JP2004115466A (ja) * | 2002-09-27 | 2004-04-15 | Toyo Shinyaku:Kk | 皮膚外用剤 |
JP2004123622A (ja) * | 2002-10-03 | 2004-04-22 | Toyo Shinyaku:Kk | 血流改善外用剤 |
FR2847471B1 (fr) | 2002-11-25 | 2006-12-29 | Expanscience Lab | Composition comprenant au moins un derive d'acide carbamique ,son utilisation cosmetique et comme medicament |
FR2847473B1 (fr) | 2002-11-25 | 2007-06-29 | Expanscience Lab | Composition comprenant au moins une oxazolidinone, son utilisation cosmetique et comme medicament |
FR2856294B1 (fr) | 2003-06-18 | 2005-08-05 | Expanscience Lab | Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite |
FR2856298B1 (fr) | 2003-06-19 | 2007-08-17 | Expanscience Lab | Extrait de maca et composition cosmetique comprenant un tel extrait |
FR2857596B1 (fr) | 2003-07-18 | 2006-02-03 | Expanscience Lab | Utilisation d'une composition cosmetique ou pharmaceutique comprenant un extrait riche en lupeol, a titre de principe actif, pour stimuler la synthese des proteines de stress |
FR2868703B1 (fr) | 2004-04-08 | 2008-06-13 | Expanscience Sa Lab | Extrait total de lupin constitue d'un extrait de sucres de lupin et d'un extrait peptidique de lupin, procede d'obtention et utilisation |
FR2869543B1 (fr) * | 2004-04-30 | 2006-07-28 | Expanscience Laboratoires Sa | Medicament comprenant un extrait peptidique d'avocat destine au traitement et la prevention des maladies liees a une deficience du systeme immunitaire |
FR2869541B1 (fr) | 2004-04-30 | 2007-12-28 | Expanscience Sa Lab | Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee |
FR2893628B1 (fr) | 2005-11-18 | 2008-05-16 | Expanscience Laboratoires Sa | Procede d'obtention d'une huile d'avocat raffinee riche en triglycerides et huile susceptible d'etre obtenue par un tel procede |
MXJL05000056A (es) * | 2005-12-19 | 2007-06-18 | Ct De Investigacion Y Asistenc | Extracto de polifenolicos a partir de la semilla de aguacate, su proceso de obtencion y usos. |
FR2903903B1 (fr) | 2006-07-18 | 2008-08-29 | Expanscience Laboratoires Sa | Utilisation d'un hydrolysat de proteines de riz en tant que principe actif pigmentant |
FR2910815B1 (fr) * | 2006-12-28 | 2010-10-29 | Expanscience Lab | Composition comprenant un extrait de graines de quinoa |
US20080305059A1 (en) * | 2007-06-06 | 2008-12-11 | Chaudhuri Ratan K | Skin lightening compositions and methods |
FR2928263B1 (fr) * | 2008-03-07 | 2010-06-18 | Oreal | Procede de traitement cosmetique a base de polyphenols de fruits ou de legumes |
WO2010100341A1 (fr) * | 2009-03-06 | 2010-09-10 | L'oreal | Procede de traitement cosmetique a base de polyphenols et d'acides de fruit, issus de fruits ou de legumes |
FR2945445B1 (fr) * | 2009-05-13 | 2012-12-14 | Oreal | Utilisation pour le maintien et/ou la fixation des fibres keratiniques d'une composition comprenant au moins un polyphenol et au moins un sucre. |
-
2010
- 2010-12-22 FR FR1061055A patent/FR2969496B1/fr active Active
-
2011
- 2011-12-22 EP EP11804575.6A patent/EP2654766B1/fr active Active
- 2011-12-22 ES ES11804575T patent/ES2704665T3/es active Active
- 2011-12-22 KR KR1020187032884A patent/KR20180125612A/ko active Application Filing
- 2011-12-22 KR KR1020237025394A patent/KR20230117253A/ko not_active Application Discontinuation
- 2011-12-22 BR BR112013015593-0A patent/BR112013015593A2/pt not_active IP Right Cessation
- 2011-12-22 WO PCT/EP2011/073832 patent/WO2012085224A1/fr active Application Filing
- 2011-12-22 KR KR1020197024257A patent/KR20190099356A/ko not_active IP Right Cessation
- 2011-12-22 US US13/824,627 patent/US20130183255A1/en not_active Abandoned
- 2011-12-22 CN CN201180062296.4A patent/CN103347528B/zh active Active
- 2011-12-22 KR KR1020217023659A patent/KR20210095741A/ko not_active IP Right Cessation
- 2011-12-22 KR KR1020137018866A patent/KR20130132548A/ko active Application Filing
- 2011-12-22 CA CA2821876A patent/CA2821876A1/fr not_active Abandoned
-
2018
- 2018-08-30 US US16/117,511 patent/US11026441B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1856293A (zh) * | 2003-09-23 | 2006-11-01 | 奥里金生物医学股份有限公司 | 多酚的无水局部用制剂 |
CN101711158A (zh) * | 2007-02-01 | 2010-05-19 | 爱默思公司 | 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104546522A (zh) * | 2014-12-18 | 2015-04-29 | 广东雅威生物科技有限公司 | 具有高效广谱抑菌能力的组合物及其在化妆品中的应用 |
CN107847401A (zh) * | 2015-05-13 | 2018-03-27 | 缪斯化妆品株式会社 | 防脱发及生发组合物 |
CN107496290A (zh) * | 2017-08-31 | 2017-12-22 | 浙江大学 | 一种提取米糠多酚的方法及应用 |
CN107714629A (zh) * | 2017-12-08 | 2018-02-23 | 林燕 | 一种含有牛油果提取物的化妆笔笔油的制备方法 |
CN107927786A (zh) * | 2017-12-28 | 2018-04-20 | 广西南宁桂尔创环保科技有限公司 | 一种从牛油果中提取多酚的方法 |
CN112074326A (zh) * | 2018-04-12 | 2020-12-11 | 化工产品开发公司Seppic | 基于多咖啡酰基奎宁酸的新型组合物、其化妆品用途和包含其的化妆品组合物 |
CN112074326B (zh) * | 2018-04-12 | 2024-03-08 | 化工产品开发公司Seppic | 基于多咖啡酰基奎宁酸的组合物、其化妆品用途和包含其的化妆品组合物 |
CN111450107A (zh) * | 2019-01-22 | 2020-07-28 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 落新妇苷有机酸组合物在治疗银屑病中的应用 |
CN112438918A (zh) * | 2019-08-30 | 2021-03-05 | 广东丸美生物技术股份有限公司 | 一种牛油果提取物及其制备方法和在抗衰老化妆品中的应用 |
CN116568157A (zh) * | 2020-09-18 | 2023-08-08 | 佩滕集团有限公司 | 发酵鳄梨颗粒及包含其的食品补充剂 |
CN113243443A (zh) * | 2021-05-10 | 2021-08-13 | 普洱丰华联合实业发展有限责任公司 | 一种牛油果咖啡及其制作方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20130132548A (ko) | 2013-12-04 |
BR112013015593A2 (pt) | 2018-05-15 |
CN103347528B (zh) | 2015-04-22 |
WO2012085224A1 (fr) | 2012-06-28 |
US20180369193A1 (en) | 2018-12-27 |
FR2969496B1 (fr) | 2013-11-08 |
US20130183255A1 (en) | 2013-07-18 |
KR20180125612A (ko) | 2018-11-23 |
KR20230117253A (ko) | 2023-08-07 |
EP2654766B1 (fr) | 2018-10-10 |
EP2654766A1 (fr) | 2013-10-30 |
FR2969496A1 (fr) | 2012-06-29 |
CA2821876A1 (fr) | 2012-06-28 |
KR20190099356A (ko) | 2019-08-26 |
KR20210095741A (ko) | 2021-08-02 |
ES2704665T3 (es) | 2019-03-19 |
US11026441B2 (en) | 2021-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103347528B (zh) | 富含多酚的鳄梨果肉和/或果皮提取物及含有它的美容用、皮肤病用和营养品用组合物 | |
US20200085897A1 (en) | Extract of Aerial Parts of Maca Rich in Polyphenols and Composition Comprising Same | |
EP2934702B1 (fr) | Extrait de graines de passiflore et compositions cosmetiques, pharmaceutiques, dermatologiques ou nutraceutiques le comprenant | |
KR101567129B1 (ko) | 아까시아 마크로스타키아 종자 추출물 및 이를 함유한 조성물 | |
CN111053716B (zh) | 一种茯茶提取物在制备皮肤调节产品中的用途 | |
JP2002138045A (ja) | 前駆脂肪細胞分化誘導剤 | |
US9370541B2 (en) | Extract of the above-ground portions of gynandropsis gynandra or cleome gynandra, and cosmetic, dermatological or pharmaceutical compositions including same | |
KR100701606B1 (ko) | 생약재 추출물을 함유한 화장료 조성물 및 그 제조방법 | |
CN105579050A (zh) | 西番莲种子的脂质提取物 | |
Pekmezci et al. | A proprietary herbal extract against hair loss in androgenetic alopecia and telogen effluvium: a placebo-controlled, single-blind, clinical-instrumental study | |
KR20140145278A (ko) | 피부 수렴 및 탄력 효과를 갖는 승마 추출물, 산수유 추출물 및 현초 추출물을 함유하는 화장료 조성물. | |
KR101347910B1 (ko) | 생강 초임계 추출물 및 발효 미나리 박 추출물을 함유하는 식품 조성물, 화장료 조성물 및 약학 조성물 | |
JP2023118853A (ja) | 抗老化用組成物、抗老化用皮膚化粧料および抗老化用飲食品 | |
JP4247091B2 (ja) | 皮膚老化防止剤 | |
TW202102239A (zh) | 抗老化劑、抗氧化劑、抗炎症劑、及美白劑、以及化妝品 | |
KR20170025363A (ko) | 피부 개선용 조성물 | |
TW201519913A (zh) | 落葵萃取物及其作為美白、防曬、抗老化、抗自由基、抗發炎之用途 | |
EA023895B1 (ru) | Средство для укрепления и стимулирования роста волос |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |